MEDICAL
NEWS
PART
CUT
HERE
LIMITS
OF
AZTS
EFFICACY
AND
NOW
SUGGEST
USING
THE
DRUG
EITHER
SEQUENTIALLY
WITH
OTHER
DRUGS
OR
IN
A
KIND
OF
AIDS
TREATMENT
COCKTAIL
COMBINING
A
NUMBER
OF
DRUGS
TO
FIGHT
THE
VIRUS
ALL
AT
ONCE
TREATING
PEOPLE
WITH
AZT
ALONE
DOESNT
HAPPEN
IN
THE
REAL
WORLD
ANYMORE
SAID
DR
MARK
JACOBSON
OF
THE
UNIVERSITY
OF
CALIFORNIASAN
FRANCISCO
ALSO
WITH
RECENT
FINDINGS
INDICATING
THAT
HIV
REPLICATES
RAPIDLY
IN
THE
LYMPH
NODES
AFTER
INFECTION
PHYSICIANS
MAY
BEGIN
PUSHING
EVEN
HARDER
FOR
EARLY
TREATMENT
OF
HIVINFECTED
PATIENTS
NEW
INFECTIOUS
DISEASE
PUSH
AMERICAN
MEDICAL
NEWS
VOL
NO
P
THE
CENTER
FOR
DISEASE
CONTROL
WILL
LAUNCH
A
WORLDWIDE
NETWORK
TO
TRACK
THE
SPREAD
OF
INFECTIOUS
DISEASES
AND
DETECT
DRUGRESISTANT
OR
NEW
STRAINS
IN
TIME
TO
HELP
PREVENT
THEIR
SPREAD
THE
NETWORK
IS
EXPECTED
TO
COST
BETWEEN
MILLION
AND
MILLION
BUT
IS
AN
ESSENTIAL
PART
OF
THE
CLINTON
ADMINISTRATIONS
HEALTH
REFORM
PLAN
ACCORDING
TO
THE
CDC
AND
OUTSIDE
EXPERTS
THE
PLAN
WILL
REQUIRE
THE
CDC
TO
ENHANCE
SURVEILLANCE
OF
DISEASE
IN
THE
UNITED
STATES
AND
ESTABLISH
ABOUT
FACILITIES
ACROSS
THE
WORLD
TO
TRACK
DISEASE
APRIL
NIH
PLANS
TO
BEGIN
AIDS
DRUG
TRIALS
AT
EARLIER
STAGE
NATURE
VOL
NO
P
MACILWAIN
COLIN
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
THE
NATIONAL
INSTITUTES
OF
HEALTH
HAS
ANNOUNCED
IT
WILL
START
TREATING
HIVPOSITIVE
PATIENTS
AS
SOON
AS
POSSIBLE
AFTER
SEROCONVERSION
RESULTING
FROM
RECENT
FINDINGS
THAT
SHOW
HIV
IS
ACTIVE
IN
THE
BODY
IN
LARGE
NUMBERS
MUCH
EARLIER
THAN
WAS
PREVIOUSLY
BELIEVED
ANTHONY
FAUCI
DIRECTOR
OF
THE
US
NATIONAL
INSTITUTE
OF
ALLERGY
AND
INFECTIOUS
DISEASES
NIAID
SAID
WE
MUST
ADDRESS
THE
QUESTION
OF
HOW
TO
TREAT
PEOPLE
AS
EARLY
AS
WE
POSSIBLY
CAN
WITH
DRUGS
THAT
ARE
SAFE
ENOUGH
TO
GIVE
PEOPLE
FOR
YEARS
AND
THAT
WILL
GET
AROUND
MICROBIAL
RESISTANCE
HE
SAID
ANY
DELAY
WOULD
SIGNIFY
QUESTIONS
OVER
SAFETY
AND
RESISTANCE
RATHER
THAN
A
LACK
OF
FUNDS
FAUCI
WHO
CO
AUTHORED
ONE
OF
THE
TWO
PAPERS
PUBLISHED
LAST
WEEK
IN
NATURE
REJECTS
THE
ARGUMENT
BY
ONE
OF
HIS
COAUTHORS
CECIL
FOX
THAT
THE
NEW
DISCOVERY
INDICATES
THAT
BILLION
SPENT
ON
VACCINE
TRIALS
HAS
BEEN
A
WASTE
OF
TIME
AND
MONEY
BECAUSE
THE
TRIALS
WERE
STARTED
TOO
LONG
AFTER
THE
PATIENTS
WERE
INFECTED
AND
WERE
ENDED
TOO
QUICKLY
JOHN
TEW
OF
THE
MEDICAL
COLLEGE
OF
VIRGINIA
IN
RICHMOND
CLAIMS
THAT
THE
NEW
EVIDENCE
STRONGLY
BACKS
THE
ARGUMENT
FOR
EARLY
TREATMENT
OF
HIVINFECTED
PATIENTS
AIDS
ACTIVISTS
WELCOMED
THE
NEW
INFORMATION
BUT
SAID
THE
SCIENTIFIC
COMMUNITY
HAS
BEEN
SLOW
TO
UNDERSTAND
THE
SIGNIFICANCE
OF
INFECTION
OF
THE
LYMPH
TISSUE
WEVE
KNOWN
ABOUT
THIS
FOR
FIVE
YEARS
BUT
WERE
GLAD
IT
IS
NOW
IN
THE
PUBLIC
DOMAIN
SAID
JESSE
DOBSON
OF
THE
CALIFORNIABASED
PROJECT
INFORM
BUT
PETER
DUESBERG
WHO
BELIEVES
THAT
AIDS
IS
INDEPENDENT
OF
HIV
AND
IS
A
RESULT
OF
DRUG
ABUSE
IN
THE
WEST
SAID
WE
ARE
SEVERAL
PARADOXES
AWAY
FROM
AN
EXPLANATION
OF
AIDSEVEN
IF
THESE
PAPERS
ARE
RIGHT
APRIL
RISK
OF
AIDS
VIRUS
FROM
DOCTORS
FOUND
TO
BE
MINIMAL
WASHINGTON
POST
P
THE
RISK
OF
HIV
BEING
TRANSMITTED
FROM
INFECTED
HEALTHCARE
PROFESSIONALS
TO
PATIENTS
IS
MINIMAL
ACCORDING
TO
NEW
RESEARCH
PUBLISHED
IN
TODAYS
JOURNAL
OF
THE
AMERICAN
MEDICAL
ASSOCIATION
JAMA
THIS
FINDING
SUPPORTS
PREVIOUS
CONCLUSIONS
BY
HEALTH
EXPERTS
THAT
THE
CHANCE
OF
CONTRACTING
HIV
FROM
A
HEALTH
CARE
WORKER
IS
REMOTE
THREE
STUDIES
IN
THE
JAMA
DEMONSTRATE
THAT
THOUSANDS
OF
PATIENTS
WERE
TREATED
BY
TWO
HIVPOSITIVE
SURGEONS
AND
DENTISTS
WITHOUT
BECOMING
INFECTED
WITH
THE
VIRUS
THE
STUDIES
WERE
CONDUCTED
BY
SEPARATE
RESEARCH
TEAMS
IN
NEW
HAMPSHIRE
MARYLAND
AND
FLORIDA
EACH
STUDY
STARTED
WITH
AN
HIVPOSITIVE
DOCTOR
OR
DENTIST
AND
TESTED
ALL
PATIENTS
WILLING
TO
PARTICIPATE
THE
NEW
HAMPSHIRE
STUDY
FOUND
THAT
NONE
OF
THE
PATIENTS
WHO
HAD
UNDERGONE
INVASIVE
PROCEDURES
BY
AN
HIVPOSITIVE
ORTHOPEDIC
SURGEON
CONTRACTED
HIV
IN
MARYLAND
OF
PATIENTS
OPERATED
ON
BY
A
BREAST
SURGERY
SPECIALIST
AT
JOHNS
HOPKINS
HOSPITAL
WERE
FOUND
TO
BE
HIVNEGATIVE
SIMILARLY
IN
FLORIDA
OF
DENTAL
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
PATIENTS
WHO
ALL
HAD
BEEN
TREATED
BY
AN
HIVPOSITIVE
GENERAL
DENTIST
WERE
TESTED
AND
FOUND
TO
BE
NEGATIVE
FOR
HIV
THE
FLORIDA
RESEARCHERS
LED
BY
GORDON
M
DICKINSON
OF
THE
UNIVERSITY
OF
MIAMI
SCHOOL
OF
MEDICINE
SAID
THIS
STUDY
INDICATES
THAT
THE
RISK
FOR
TRANSMISSION
OF
HIV
FROM
A
GENERAL
DENTIST
TO
HIS
PATIENTS
IS
MINIMAL
IN
A
SETTING
IN
WHICH
UNIVERSAL
PRECAUTIONS
ARE
STRICTLY
OBSERVED
RELATED
STORY
PHILADELPHIA
INQUIRER
P
ALTERNATIVE
MEDICINE
ADVOCATES
DIVIDED
OVER
NEW
NIH
RESEARCH
PROGRAM
AIDS
TREATMENT
NEWS
NO
P
GILDEN
DAVE
THE
NEW
OFFICE
OF
ALTERNATIVE
MEDICINE
AT
THE
NATIONAL
INSTITUTES
OF
HEALTH
HAS
RAISED
QUESTIONS
ABOUT
THE
NIHS
COMMITMENT
TO
AN
EFFORT
THAT
USES
UNORTHODOX
OR
HOLISTIC
THERAPEUTIC
METHODS
THE
OAM
IS
A
SMALL
DIVISION
OF
THE
NIH
WITH
ITS
BUDGET
ONLY
AT
MILLION
DOLLARS
COMPARED
TO
MORE
THAN
BILLION
FOR
THE
NIH
AS
A
WHOLE
IN
ADDITION
THE
MONEY
FOR
AVAILABLE
RESEARCH
GRANTS
IS
EVEN
SMALLER
ABOUT
TO
TOTAL
WILL
BE
AVAILABLE
THIS
YEAR
FOR
OR
GRANTS
KAIYA
MONTAOCEAN
OF
THE
CENTER
FOR
NATURAL
AND
TRADITIONAL
MEDICINE
IN
WASHINGTON
DC
SAYS
THE
OAM
IS
AFRAID
TO
BECOME
INVOLVED
IN
AIDS
THEY
HAVE
TO
LOOK
SUCCESSFUL
AND
THERE
IS
NO
EASY
ANSWER
IN
AIDS
SHE
SAID
THERE
IS
ALSO
A
COMMON
PERCEPTION
THAT
THE
OAM
WILL
FOCUS
ON
FIELDS
THE
NIH
ESTABLISHMENT
WILL
FIND
NONTHREATENING
SUCH
AS
RELAXATION
TECHNIQUES
AND
ACUPUNCTURE
WHEN
THE
OAM
CALLED
FOR
AN
ADVISORY
COMMITTEE
CONFERENCE
OF
ABOUT
PEOPLE
LAST
YEAR
THE
AIDS
COMMUNITY
WAS
LARGELY
MISSING
FROM
THE
MEETING
IN
ADDITION
ACTIVISTS
GENERAL
LACK
OF
CONTACT
WITH
THE
OFFICE
HAS
ADDED
SUSPICION
THAT
THE
EPIDEMIC
WILL
BE
IGNORED
JON
GREENBERG
OF
ACTUPNEW
YORK
SAID
THE
OAM
ADVISORY
PANEL
IS
COMPOSED
OF
PRACTITIONERS
WITHOUT
REAL
RESEARCH
EXPERIENCE
IT
WILL
TAKE
THEM
SEVERAL
YEARS
TO
ACCEPT
THE
NATURE
OF
RESEARCH
NEVERTHELESS
DR
LEANNA
STANDISH
RESEARCH
DIRECTOR
AND
AIDS
INVESTIGATOR
AT
THE
BASTYR
COLLEGE
OF
NATUROPATHIC
MEDICINE
IN
SEATTLE
SAID
HERE
IS
A
WONDERFUL
OPPORTUNITY
TO
FUND
AIDS
RESEARCH
ITS
ONLY
FAIR
TO
GIVE
THE
OFFICE
TIME
TO
GEL
BUT
ITS
UP
TO
THE
PUBLIC
TO
INSIST
THAT
ITS
MUCH
MUCH
MORE
THAN
PUBLIC
RELATIONS
HERPESVIRUS
DECIMATES
IMMUNECELL
SOLDIERS
SCIENCE
NEWS
VOL
NO
P
FACKELMANN
KATHY
A
SCIENTISTS
CONDUCTING
TEST
TUBE
EXPERIMENTS
HAVE
FOUND
THAT
HERPESVIRUS
CAN
ATTACK
THE
HUMAN
IMMUNE
SYSTEMS
NATURAL
KILLER
CELLS
THIS
ATTACK
CAUSES
THE
KILLER
CELLS
TO
MALFUNCTION
DIMINISHING
AN
IMPORTANT
COMPONENT
IN
THE
IMMUNE
SYSTEMS
FIGHT
AGAINST
DISEASES
ALSO
THE
MAY
BE
A
FACTOR
IN
IMMUNE
DISEASES
SUCH
AS
AIDS
IN
PAOLO
LUSSOS
RESEARCH
FOUND
THAT
ATTACKS
ANOTHER
WHITE
CELL
THE
TLYMPHOCYTE
WHICH
IS
THE
PRIMARY
TARGET
OF
HIV
LUSSO
ALSO
FOUND
THAT
CAN
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
KILL
NATURAL
KILLER
CELLS
SCIENTISTS
PREVIOUSLY
KNEW
THAT
THE
NATURAL
KILLER
CELLS
OF
PATIENTS
INFECTED
WITH
HIV
DO
NOT
WORK
CORRECTLY
LUSSOS
RESEARCH
REPRESENTS
THE
FIRST
TIME
SCIENTISTS
HAVE
INDICATED
THAT
NATURAL
KILLER
CELLS
ARE
VULNERABLE
TO
ANY
KIND
OF
VIRAL
ATTACK
ACCORDING
TO
ANTHONY
L
KOMAROFF
A
RESEARCHER
WITH
HARVARD
MEDICAL
SCHOOL
DESPITE
THE
TESTTUBE
FINDINGS
SCIENTISTS
ARE
UNCERTAIN
WHETHER
THE
SAME
RESULT
OCCURS
IN
THE
BODY
LUSSOS
TEAM
ALSO
FOUND
THAT
PRODUCES
THE
RECEPTOR
MOLECULE
THAT
PROVIDES
ACCESS
FOR
HIV
TLYMPHOCYTES
EXPRESS
THIS
SURFACE
RECEPTOR
MAKING
THEM
VULNERABLE
TO
HIVS
ATTACK
RESEARCHERS
CONCLUDED
THAT
CELLS
CAN
EXACERBATE
THE
AFFECTS
OF
HIV
APRIL
AIDS
AND
PRIORITIES
IN
THE
GLOBAL
VILLAGE
TO
THE
EDITOR
JOURNAL
OF
THE
AMERICAN
MEDICAL
ASSOCIATION
VOL
NO
P
GELLERT
GEORGE
AND
NORDENBERG
DALE
F
ALL
HEALTHCARE
WORKERS
ARE
OBLIGATED
AND
RESPONSIBLE
FOR
NOT
ONLY
ENSURING
THAT
POLITICIANS
UNDERSTAND
THE
DIMENSIONS
OF
CERTAIN
HEALTH
PROBLEMS
BUT
ALSO
TO
BE
COMMITTED
TO
RELATED
POLICIES
WRITE
GEORGE
GELLERT
AND
DALE
F
NORDENBERG
OF
THE
ORANGE
COUNTY
HEALTH
CARE
AGENCY
SANTA
ANA
CALIF
AND
THE
EMORY
UNIVERSITY
SCHOOL
OF
PUBLIC
HEALTH
IN
ATLANTA
GA
RESPECTIVELY
DR
BERKLEYS
EDITORIAL
ON
WHY
AMERICAN
DOCTORS
SHOULD
CARE
ABOUT
THE
AIDS
EPIDEMIC
BEYOND
THE
UNITED
STATES
DETAILS
SEVERAL
REASONS
FOR
THE
CONCERTED
INTEREST
THAT
ALL
COUNTRIES
SHARE
IN
COMBATING
AIDS
IT
SHOULD
BE
NOTED
THAT
WHILE
AIDS
LEADS
IN
HASTENING
GLOBAL
HEALTH
INTERDEPENDENCE
IT
IS
NOT
THE
ONLY
ILLNESS
DOING
SO
DISEASES
SUCH
AS
MALARIA
AND
MANY
RESPIRATORY
AND
INTESTINAL
PATHOGENS
HAVE
SIMILARLY
INHIBITED
THE
ECONOMIC
DEVELOPMENT
OF
MOST
OF
HUMANITY
AND
ACTED
TO
MARGINALIZE
LARGE
POPULATIONS
BERKLEY
MENTIONS
THE
ENORMOUS
SOCIAL
AND
ECONOMIC
IMPACT
THAT
AIDS
WILL
HAVE
ON
MANY
DEVELOPING
COUNTRIES
AND
THE
INCREASED
NEED
FOR
INTERNATIONAL
ASSISTANCE
THAT
WILL
RESULT
BERKLEY
ALSO
CITES
THE
LACK
OF
POLITICAL
AGGRESSIVENESS
TOWARD
THE
AIDS
EPIDEMIC
IN
ITS
FIRST
DECADE
BUT
NOW
THERE
IS
A
NEW
ADMINISTRATION
WITH
A
PROMISE
OF
SUBSTANTIAL
DIFFERENCES
IN
APPROACH
TO
INTERNATIONAL
HEALTH
AND
DEVELOPMENT
IN
GENERAL
AND
HIVAIDS
IN
PARTICULAR
VICE
PRESIDENT
AL
GORE
PROPOSES
IN
HIS
BOOK
EARTH
IN
THE
BALANCE
A
MAJOR
ENVIRONMENTAL
INITIATIVE
THAT
INCLUDES
SUSTAINABLE
INTERNATIONAL
DEVELOPMENT
WITH
PROGRAMS
TO
PROMOTE
LITERACY
IMPROVE
CHILD
SURVIVAL
AND
DISSEMINATE
CONTRACEPTIVE
TECHNOLOGY
AND
ACCESS
THROUGHOUT
THE
DEVELOPING
WORLD
IF
ENACTED
THIS
CHANGE
IN
POLICY
COULD
DRASTICALLY
CHANGE
THE
FUTURE
OF
WORLDWIDE
HEALTH
AIDS
AND
PRIORITIES
IN
THE
GLOBAL
VILLAGE
IN
REPLY
JOURNAL
OF
THE
AMERICAN
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
MEDICAL
ASSOCIATION
VOL
NO
P
BERKLEY
SETH
EVERY
NATION
SHOULD
TACKLE
HIV
AS
EARLY
AND
AGGRESSIVELY
AS
POSSIBLE
BEFORE
THE
DISEASE
REACHES
AN
ENDEMIC
STATE
EVEN
AT
A
COST
OF
DIVERTING
LESS
ATTENTION
TO
SOME
OTHER
ILLNESSES
WRITES
SETH
BERKLEY
OF
THE
ROCKEFELLER
FOUNDATION
IN
NEW
YORK
NY
IN
REPLY
TO
A
LETTER
BY
DRS
GELLERT
AND
NORDENBERG
ALTHOUGH
IT
IS
TRUE
THAT
DISEASES
OTHER
THAN
AIDS
SUCH
AS
MALARIA
AND
RESPIRATORY
AND
INTESTINAL
ILLNESSES
HAVE
SIMILARLY
INHIBITED
ECONOMIC
DEVELOPMENT
IN
DEVELOPING
COUNTRIES
AND
DESERVE
MUCH
MORE
ATTENTION
THAN
THEY
ARE
GETTING
BERKLEY
DISAGREES
WITH
THE
CONTENTION
THAT
AIDS
IS
RECEIVING
TOO
MUCH
ATTENTION
HIV
DIFFERS
FROM
OTHER
DISEASES
IN
MOST
DEVELOPING
COUNTRIES
BECAUSE
IT
IS
CONTINUING
TO
SPREAD
FOR
MOST
ENDEMIC
DISEASES
THE
OUTCOME
OF
NEGLECTING
INTERVENTIONS
FOR
ONE
YEAR
IS
ANOTHER
YEAR
OF
ABOUT
THE
SAME
LEVEL
OF
NEEDLESS
DISEASE
AND
DEATH
BUT
WITH
AIDS
AND
ITS
INCREASING
SPREAD
THE
COST
OF
NEGLECT
NOT
ONLY
IN
DISEASE
BURDEN
BUT
FINANCIALLY
IS
MUCH
GREATER
INTERVENTIONS
IN
THE
EARLY
PART
OF
A
RAMPANTLY
SPREADING
EPIDEMIC
LIKE
HIV
ARE
HIGHLY
COSTEFFECTIVE
BECAUSE
EACH
INDIVIDUAL
INFECTION
PREVENTED
SIGNIFICANTLY
INTERRUPTS
TRANSMISSION
BERKLEY
SAYS
HE
AGREES
WITH
GELLERT
AND
NORDENBERG
ABOUT
THE
GIGANTIC
SOCIAL
AND
ECONOMIC
EFFECTS
OF
AIDS
AND
ABOUT
THE
NEED
FOR
POLITICAL
LEADERSHIP
BUT
HE
CONCLUDES
THAT
NOT
ONLY
IS
ASSERTIVE
POLITICAL
LEADERSHIP
NEEDED
IN
THE
UNITED
STATES
FOR
THE
AIDS
EPIDEMIC
BUT
EVEN
MORE
SO
IN
DEVELOPING
COUNTRIES
WITH
HIGH
RATES
OF
HIV
INFECTION
AND
WHERE
COMPLACENCY
ABOUT
THE
EPIDEMIC
HAS
BEEN
THE
RULE
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
AIDSHIV
ARTICLES
FIRST
HIV
VACCINE
TRIAL
BEGINS
IN
HIVINFECTED
CHILDREN
H
H
S
N
E
W
S
US
DEPARTMENT
OF
HEALTH
AND
HUMAN
SERVICES
MARCH
FIRST
HIV
VACCINE
THERAPY
TRIAL
BEGINS
IN
HIVINFECTED
CHILDREN
THE
NATIONAL
INSTITUTES
OF
HEALTH
HAS
OPENED
THE
FIRST
TRIAL
OF
EXPERIMENTAL
HIV
VACCINES
IN
CHILDREN
WHO
ARE
INFECTED
WITH
THE
HUMAN
IMMUNODEFICIENCY
VIRUS
HIV
THE
VIRUS
THAT
CAUSES
AIDS
THE
TRIAL
WILL
COMPARE
THE
SAFETY
OF
THREE
HIV
EXPERIMENTAL
VACCINES
IN
CHILDREN
RECRUITED
FROM
AT
LEAST
SITES
NATIONWIDE
VOLUNTEERS
MUST
BE
HIV
INFECTED
BUT
HAVE
NO
SYMPTOMS
OF
HIV
DISEASE
HHS
SECRETARY
DONNA
E
SHALALA
SAID
THIS
INITIAL
STUDY
CAN
BE
SEEN
AS
A
HOPEFUL
MILESTONE
IN
OUR
EFFORTS
TO
AMELIORATE
THE
TRAGEDY
OF
HIVINFECTED
CHILDREN
WHO
NOW
FACE
THE
CERTAINTY
THEY
WILL
DEVELOP
AIDS
ANTHONY
S
FAUCI
MD
DIRECTOR
OF
THE
NATIONAL
INSTITUTE
OF
ALLERGY
AND
INFECTIOUS
DISEASES
AND
OF
THE
NIH
OFFICE
OF
AIDS
RESEARCH
SAID
THE
TRIAL
IS
THE
FIRST
STEP
IN
FINDING
OUT
WHETHER
VACCINES
CAN
HELP
PREVENT
OR
DELAY
DISEASE
PROGRESSION
IN
CHILDREN
WITH
HIV
WHO
ARE
NOT
YET
SICK
IF
THESE
VACCINES
PROVE
TO
BE
SAFE
MORE
SOPHISTICATED
QUESTIONS
ABOUT
THEIR
THERAPEUTIC
POTENTIAL
WILL
BE
ASSESSED
IN
PHASE
II
TRIALS
THE
CENTERS
FOR
DISEASE
CONTROL
AND
PREVENTION
ESTIMATES
CHILDREN
IN
THE
UNITED
STATES
HAVE
HIV
BY
THE
END
OF
THE
DECADE
THE
WORLD
HEALTH
ORGANIZATION
PROJECTS
MILLION
CHILDREN
WILL
BE
INFECTED
WORLDWIDE
THE
STUDY
WILL
ENROLL
CHILDREN
AGES
MONTH
TO
YEARS
OLD
NIAID
WHICH
FUNDS
THE
AIDS
CLINICAL
TRIALS
GROUP
NETWORK
ANTICIPATES
CONDUCTING
THE
TRIAL
AT
NINE
ACTG
SITES
AROUND
THE
COUNTRY
AND
THREE
SITES
PARTICIPATING
IN
THE
ACTG
BUT
FUNDED
BY
THE
NATIONAL
INSTITUTE
OF
CHILD
HEALTH
AND
HUMAN
DEVELOPMENT
PRELIMINARY
EVIDENCE
FROM
SIMILAR
STUDIES
UNDER
WAY
IN
INFECTED
ADULTS
SHOWS
THAT
CERTAIN
VACCINES
CAN
BOOST
EXISTING
HIVSPECIFIC
IMMUNE
RESPONSES
AND
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
STIMULATE
NEW
ONES
IT
WILL
BE
SEVERAL
YEARS
HOWEVER
BEFORE
RESEARCHERS
KNOW
HOW
THESE
RESPONSES
AFFECT
THE
CLINICAL
COURSE
OF
THE
DISEASE
THE
RESULTS
FROM
THE
PEDIATRIC
TRIAL
KNOWN
AS
ACTG
WILL
BE
EXAMINED
CLOSELY
FOR
OTHER
REASONS
AS
WELL
THIS
TRIAL
WILL
PROVIDE
THE
FIRST
INSIGHT
INTO
HOW
THE
IMMATURE
IMMUNE
SYSTEM
RESPONDS
TO
CANDIDATE
HIV
VACCINES
SAID
DANIEL
HOTH
MD
DIRECTOR
OF
NIAIDS
DIVISION
OF
AIDS
WE
NEED
THIS
INFORMATION
TO
DESIGN
TRIALS
TO
TEST
WHETHER
EXPERIMENTAL
VACCINES
CAN
PREVENT
HIV
INFECTION
IN
CHILDREN
IN
THE
UNITED
STATES
MOST
HIVINFECTED
CHILDREN
LIVE
IN
POOR
INNERCITY
AREAS
AND
MORE
THAN
PERCENT
ARE
MINORITIES
MAINLY
BLACK
OR
HISPANIC
NEARLY
ALL
HIVINFECTED
CHILDREN
ACQUIRE
THE
VIRUS
FROM
THEIR
MOTHERS
DURING
PREGNANCY
OR
AT
BIRTH
AN
INFECTED
MOTHER
IN
THE
UNITED
STATES
HAS
MORE
THAN
A
ONE
IN
FOUR
CHANCE
OF
TRANSMITTING
THE
VIRUS
TO
HER
BABY
AS
GROWING
NUMBERS
OF
WOMEN
OF
CHILDBEARING
AGE
BECOME
EXPOSED
TO
HIV
THROUGH
INJECTION
DRUG
USE
OR
INFECTED
SEXUAL
PARTNERS
RESEARCHERS
EXPECT
A
CORRESPONDING
INCREASE
IN
THE
NUMBERS
OF
INFECTED
CHILDREN
HIV
DISEASE
PROGRESSES
MORE
RAPIDLY
IN
INFANTS
AND
CHILDREN
THAN
IN
ADULTS
THE
MOST
RECENT
INFORMATION
SUGGESTS
THAT
PERCENT
OF
INFANTS
BORN
WITH
HIV
DEVELOP
A
SERIOUS
AIDSRELATED
INFECTION
BY
TO
YEARS
OF
AGE
THESE
INFECTIONS
INCLUDE
SEVERE
OR
FREQUENT
BOUTS
OF
COMMON
BACTERIAL
ILLNESSES
OF
CHILDHOOD
THAT
CAN
RESULT
IN
SEIZURES
PNEUMONIA
DIARRHEA
AND
OTHER
SYMPTOMS
LEADING
TO
NUTRITIONAL
PROBLEMS
AND
LONG
HOSPITAL
STAYS
AT
LEAST
HALF
OF
THE
CHILDREN
IN
THE
TRIAL
WILL
BE
YEARS
OF
AGE
OR
YOUNGER
TO
ENABLE
COMPARISON
OF
THE
IMMUNE
RESPONSES
OF
THE
YOUNGER
AND
OLDER
PARTICIPANTS
ALL
VOLUNTEERS
MUST
HAVE
WELLDOCUMENTED
HIV
INFECTION
BUT
NO
SYMPTOMS
OF
HIV
DISEASE
OTHER
THAN
SWOLLEN
LYMPH
GLANDS
OR
A
MILDLY
SWOLLEN
LIVER
OR
SPLEEN
THEY
CANNOT
HAVE
RECEIVED
ANY
ANTIRETROVIRAL
OR
IMMUNE
REGULATING
DRUGS
WITHIN
ONE
MONTH
PRIOR
TO
THEIR
ENTRY
INTO
THE
STUDY
STUDY
CHAIR
JOHN
S
LAMBERT
MD
OF
THE
UNIVERSITY
OF
ROCHESTER
MEDICAL
SCHOOL
AND
CO
CHAIR
SAMUEL
KATZ
MD
OF
DUKE
UNIVERSITY
SCHOOL
OF
MEDICINE
WILL
COORDINATE
THE
TRIAL
ASSISTED
BY
JAMES
MCNAMARA
MD
MEDICAL
OFFICER
IN
THE
PEDIATRIC
MEDICINE
BRANCH
OF
NIAIDS
DIVISION
OF
AIDS
WE
WILL
COMPARE
THE
SAFETY
OF
THE
VACCINES
BY
CLOSELY
MONITORING
THE
CHILDREN
FOR
ANY
SIDE
EFFECTS
TO
SEE
IF
ONE
VACCINE
PRODUCES
MORE
SWOLLEN
ARMS
OR
FEVERS
FOR
EXAMPLE
THAN
ANOTHER
SAID
DR
MCNAMARA
WELL
ALSO
LOOK
AT
WHETHER
LOW
OR
HIGH
DOSES
OF
THE
VACCINES
STIMULATE
IMMUNE
RESPONSES
OR
OTHER
SIGNIFICANT
LABORATORY
OR
CLINICAL
EFFECTS
HE
EMPHASIZED
THAT
THE
SMALL
STUDY
SIZE
PRECLUDES
COMPARING
THESE
RESPONSES
OR
EFFECTS
AMONG
THE
THREE
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
PRODUCTS
THE
TRIAL
WILL
TEST
TWO
DOSES
EACH
OF
THREE
EXPERIMENTAL
VACCINES
MADE
FROM
RECOMBINANT
HIV
PROTEINS
THESE
SOCALLED
SUBUNIT
VACCINES
EACH
GENETICALLY
ENGINEERED
TO
CONTAIN
ONLY
A
PIECE
OF
THE
VIRUS
HAVE
SO
FAR
PROVED
WELL
TOLERATED
IN
ONGOING
TRIALS
IN
HIVINFECTED
ADULTS
ONE
VACCINE
MADE
BY
MICROGENESYS
INC
OF
MERIDEN
CONN
CONTAINS
PROTEIN
THAT
GIVES
RISE
TO
HIVS
SURFACE
PROTEINSPLUS
ALUM
ADJUVANT
ADJUVANTS
BOOST
SPECIFIC
IMMUNE
RESPONSES
TO
A
VACCINE
PRESENTLY
ALUM
IS
THE
ONLY
ADJUVANT
USED
IN
HUMAN
VACCINES
LICENSED
BY
THE
FOOD
AND
DRUG
ADMINISTRATION
BOTH
OF
THE
OTHER
VACCINESONE
MADE
BY
GENENTECH
INC
OF
SOUTH
SAN
FRANCISCO
AND
THE
OTHER
BY
BIOCINE
A
JOINT
VENTURE
OF
CHIRON
AND
CIBAGEIGY
IN
EMERYVILLE
CALIFCONTAIN
THE
MAJOR
HIV
SURFACE
PROTEIN
PLUS
ADJUVANT
THE
GENENTECH
VACCINE
CONTAINS
ALUM
WHILE
THE
BIOCINE
VACCINE
CONTAINS
AN
EXPERIMENTAL
ADJUVANT
THAT
HAS
PROVED
SAFE
AND
EFFECTIVE
IN
OTHER
PHASE
I
VACCINE
TRIALS
IN
ADULTS
A
LOW
DOSE
OF
EACH
PRODUCT
WILL
BE
TESTED
FIRST
AGAINST
A
PLACEBO
IN
CHILDREN
TWELVE
CHILDREN
WILL
BE
ASSIGNED
AT
RANDOM
TO
BE
IMMUNIZED
WITH
THE
EXPERIMENTAL
VACCINE
AND
THREE
CHILDREN
WILL
BE
GIVEN
ADJUVANT
ALONE
CONSIDERED
THE
PLACEBO
NEITHER
THE
HEALTH
CARE
WORKERS
NOR
THE
CHILDREN
WILL
BE
TOLD
WHAT
THEY
RECEIVE
IF
THE
LOW
DOSE
IS
WELLTOLERATED
CONTROLLED
TESTING
OF
A
HIGHER
DOSE
OF
THE
EXPERIMENTAL
VACCINE
AND
ADJUVANT
PLACEBO
IN
ANOTHER
GROUP
OF
CHILDREN
WILL
BEGIN
EACH
CHILD
WILL
RECEIVE
SIX
IMMUNIZATIONSONE
EVERY
FOUR
WEEKS
FOR
SIX
MONTHSAND
BE
FOLLOWEDUP
FOR
WEEKS
AFTER
THE
LAST
IMMUNIZATION
FOR
MORE
INFORMATION
ABOUT
THE
TRIAL
SITES
OR
ELIGIBILITY
FOR
ENROLLMENT
CALL
THE
AIDS
CLINICAL
TRIALS
INFORMATION
SERVICE
FROM
AM
TO
PM
EST
WEEKDAYS
THE
SERVICE
HAS
SPANISHSPEAKING
INFORMATION
SPECIALISTS
AVAILABLE
INFORMATION
ON
NIAIDS
PEDIATRIC
HIVAIDS
RESEARCH
IS
AVAILABLE
FROM
THE
OFFICE
OF
COMMUNICATIONS
AT
NIH
CDC
AND
FDA
ARE
AGENCIES
OF
THE
US
PUBLIC
HEALTH
SERVICE
IN
HHS
FOR
PRESS
INQUIRIES
ONLY
PLEASE
CALL
LAURIE
K
DOEPEL
AT
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
NEW
EVIDENCE
THAT
THE
HIV
CAN
CAUSE
DISEASE
INDEPENDENTLY
NEWS
FROM
THE
NATIONAL
INSTITUTE
OF
DENTAL
RESEARCH
THERE
IS
NEW
EVIDENCE
THAT
THE
HUMAN
IMMUNODEFICIENCY
VIRUS
CAN
CAUSE
DISEASE
INDEPENDENTLY
OF
ITS
ABILITY
TO
SUPPRESS
THE
IMMUNE
SYSTEM
SAY
SCIENTISTS
AT
THE
NATIONAL
INSTITUES
OF
HEALTH
THEY
REPORT
THAT
HIV
ITSELF
NOT
AN
OPPORTUNISTIC
INFECTION
CAUSED
SCALING
SKIN
CONDITIONS
TO
DEVELOP
IN
MICE
CARRYING
THE
GENES
FOR
HIV
ALTHOUGH
THE
HIV
GENES
WERE
ACTIVE
IN
THE
MICE
THEY
DID
NOT
COMPROMISE
THE
ANIMALS
IMMUNITY
THE
RESEARCHERS
FOUND
THIS
LED
THEM
TO
CONCLUDE
THAT
THE
HIV
ITSELF
CAUSED
THE
SKIN
DISEASE
OUR
FINDINGS
SUPPORT
A
GROWING
BODY
OF
EVIDENCE
THAT
HIV
CAN
CAUSE
DISEASE
WITHOUT
AFFECTING
THE
IMMUNE
SYSTEM
SAID
LEAD
AUTHOR
DR
JEFFREY
KOPP
OF
THE
NATIONAL
INSTITUTE
OF
DENTAL
RESEARCH
NIDR
DR
KOPP
AND
HIS
COLLEAGUES
DESCRIBED
THEIR
STUDY
IN
THE
MARCH
ISSUE
OF
AIDS
RESEARCH
AND
HUMAN
RETROVIRUSES
DEVELOPING
ANIMAL
MODELS
OF
HIV
INFECTION
HAS
BEEN
DIFFICULT
SINCE
MOST
ANIMALS
INCLUDING
MICE
CANNOT
BE
INFECTED
BY
THE
VIRUS
TO
BYPASS
THIS
PROBLEM
SCIENTISTS
HAVE
DEVELOPED
HIVTRANSGENIC
MICE
WHICH
CARRY
GENES
FOR
HIV
AS
WELL
AS
THEIR
OWN
GENETIC
MATERIAL
NIDR
SCIENTISTS
CREATED
THE
TRANSGENIC
MICE
BY
INJECTING
HIV
GENES
INTO
MOUSE
EGGS
AND
THEN
IMPLANTING
THE
EGGS
INTO
FEMALE
MICE
THE
RESULTING
LITTERS
CONTAINED
BOTH
NORMAL
AND
TRANSGENIC
ANIMALS
INSTITUTE
SCIENTISTS
HAD
CREATED
MICE
THAT
CARRIED
A
COMPLETE
COPY
OF
HIV
GENETIC
MATERIAL
IN
THOSE
MICE
HOWEVER
BECAME
SICK
AND
DIED
TOO
SOON
AFTER
BIRTH
TO
STUDY
IN
DEPTH
IN
THE
PRESENT
STUDY
THE
SCIENTISTS
USED
AN
INCOMPLETE
COPY
OF
HIV
WHICH
ALLOWED
THE
ANIMALS
TO
LIVE
LONGER
SOME
OF
THE
TRANSGENIC
ANIMALS
DEVELOPED
SCALING
WARTLIKE
TUMORS
ON
THEIR
NECKS
AND
BACKS
OTHER
TRANSGENIC
MICE
DEVELOPED
THICKENED
CRUSTING
SKIN
LESIONS
THAT
COVERED
MOST
OF
THEIR
BODIES
RESEMBLING
PSORIASIS
IN
HUMANS
NO
SKIN
LESIONS
DEVELOPED
IN
THEIR
NORMAL
NONTRANSGENIC
LITTERMATES
STUDIES
OF
TISSUE
TAKEN
FROM
THE
WARTLIKE
SKIN
TUMORS
SHOWED
THAT
THEY
WERE
A
TYPE
OF
NONCANCEROUS
TUMOR
CALLED
PAPILLOMA
ALTHOUGH
THE
PAPILLOMAVIRUS
CAN
CAUSE
THESE
SKIN
LESIONS
LABORATORY
TESTS
SHOWED
NO
SIGN
OF
THAT
VIRUS
IN
THE
ANIMALS
TISSUE
SAMPLES
TAKEN
FROM
THE
SICK
MICE
THROUGHOUT
THE
STUDY
REVEALED
THE
PRESENCE
OF
A
PROTEINPRODUCING
MOLECULE
MADE
BY
THE
HIV
GENETIC
MATERIAL
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
EVIDENCE
OF
HIV
PROTEIN
PRODUCTION
PROVED
THAT
THE
VIRAL
GENES
WERE
TURNED
ON
OR
ACTIVE
SAID
DR
KOPP
THE
SCIENTISTS
FOUND
NO
EVIDENCE
HOWEVER
OF
COMPROMISED
IMMUNITY
IN
THE
MICE
NO
INCREASE
IN
THEIR
WHITE
BLOOD
CELL
COUNT
AND
NO
SIGNS
OF
COMMON
INFECTIONS
THE
FACT
THAT
HIV
GENES
WERE
ACTIVE
BUT
THE
ANIMALS
IMMUNE
SYSTEMS
WERE
NOT
SUPPRESSED
CONFIRMS
THAT
THE
VIRUS
ITSELF
WAS
CAUSING
THE
SKIN
LESIONS
DR
KOPP
SAID
FURTHER
PROOF
OF
HIV
GENE
INVOLVEMENT
CAME
FROM
A
TEST
IN
WHICH
THE
SCIENTISTS
EXPOSED
THE
TRANSGENIC
ANIMALS
TO
ULTRAVIOLET
LIGHT
THE
LIGHT
INCREASED
HIV
GENETIC
ACTIVITY
CAUSING
PAPILLOMAS
TO
DEVELOP
ON
FORMERLY
HEALTHY
SKIN
PAPILLOMA
FORMATION
IN
RESPONSE
TO
INCREASED
HIV
GENETIC
ACTIVITY
PROVED
THE
GENES
WERE
RESPONSIBLE
FOR
THE
SKIN
CONDITION
THE
SCIENTISTS
SAID
NO
LESIONS
APPEARED
ON
NORMAL
MICE
EXPOSED
TO
THE
UV
LIGHT
THE
TRANSGENIC
MICE
USED
IN
THIS
STUDY
WERE
DEVELOPED
AT
NIDR
BY
DR
PETER
DICKIE
WHO
IS
NOW
WITH
THE
NATIONAL
INSTITUTE
OF
ALLERGY
AND
INFECTIOUS
DISEASES
COLLABORATING
ON
THE
STUDY
WITH
DR
KOPP
WERE
MR
CHARLES
WOHLENBERG
DRS
NICKOLAS
DORFMAN
JOSEPH
BRYANT
ABNER
NOTKINS
AND
PAUL
KLOTMAN
ALL
OF
NIDR
DR
STEPHEN
KATZ
OF
THE
NATIONAL
CANCER
INSTITUTE
AND
DR
JAMES
ROONEY
FORMERLY
WITH
NIDR
AND
NOW
WITH
BURROUGHS
WELLCOME
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
CLINICAL
CONSULTATION
TELEPHONE
SERVICE
FOR
AIDS
H
H
S
N
E
W
S
US
DEPARTMENT
OF
HEALTH
AND
HUMAN
SERVICES
MARCH
HHS
SECRETARY
DONNA
E
SHALALA
TODAY
ANNOUNCED
THE
FIRST
NATIONWIDE
CLINICAL
CONSULTATION
TELEPHONE
SERVICE
FOR
DOCTORS
AND
OTHER
HEALTH
CARE
PROFESSIONALS
WHO
HAVE
QUESTIONS
ABOUT
PROVIDING
CARE
TO
PEOPLE
WITH
HIV
INFECTION
OR
AIDS
THE
TOLLFREE
NATIONAL
HIV
TELEPHONE
CONSULTING
SERVICE
IS
STAFFED
BY
A
PHYSICIAN
A
NURSE
PRACTITIONER
AND
A
PHARMACIST
IT
PROVIDES
INFORMATION
ON
DRUGS
CLINICAL
TRIALS
AND
THE
LATEST
TREATMENT
METHODS
THE
SERVICE
IS
FUNDED
BY
THE
HEALTH
RESOURCES
AND
SERVICES
ADMINISTRATION
AND
OPERATES
OUT
OF
SAN
FRANCISCO
GENERAL
HOSPITAL
SECRETARY
SHALALA
SAID
ONE
GOAL
OF
THIS
PROJECT
IS
TO
SHARE
EXPERTISE
SO
PATIENTS
GET
THE
BEST
CARE
A
SECOND
GOAL
IS
TO
GET
MORE
PRIMARY
HEALTH
CARE
PROVIDERS
INVOLVED
IN
CARE
FOR
PEOPLE
WITH
HIV
OR
AIDS
WHICH
REDUCES
TREATMENT
COST
BY
ALLOWING
PATIENTS
TO
REMAIN
WITH
THEIR
MEDICAL
PROVIDERS
AND
COMMUNITY
SOCIAL
SUPPORT
NETWORKS
CURRENTLY
MANY
PROVIDERS
REFER
PATIENTS
WITH
HIV
OR
AIDS
TO
SPECIALISTS
OR
OTHER
PROVIDERS
WHO
HAVE
MORE
EXPERIENCE
SECRETARY
SHALALA
SAID
THIS
CLINICAL
EXPERTISE
SHOULD
BE
ESPECIALLY
HELPFUL
FOR
PHYSICIANS
AND
PROVIDERS
WHO
TREAT
PEOPLE
WITH
HIV
OR
AIDS
IN
COMMUNITIES
AND
CLINICAL
SITES
WHERE
HIV
EXPERTISE
IS
NOT
READILY
AVAILABLE
THE
TELEPHONE
NUMBER
FOR
HEALTH
CARE
PROFESSIONALS
IS
AND
IT
IS
ACCESSIBLE
FROM
AM
TO
PM
EST
AM
TO
PM
PST
MONDAY
THROUGH
FRIDAY
DURING
THESE
TIMES
CONSULTANTS
WILL
TRY
TO
ANSWER
QUESTIONS
IMMEDIATELY
OR
WITHIN
AN
HOUR
AT
OTHER
TIMES
PHYSICIANS
AND
HEALTH
CARE
PROVIDERS
CAN
LEAVE
AN
ELECTRONIC
MESSAGE
AND
QUESTIONS
WILL
BE
ANSWERED
AS
QUICKLY
AS
POSSIBLE
HEALTH
CARE
PROFESSIONALS
MAY
CALL
THE
SERVICE
TO
ASK
ANY
QUESTION
RELATED
TO
PROVIDING
HIV
CARE
INCLUDING
THE
LATEST
HIVAIDS
DRUG
TREATMENT
INFORMATION
CLINICAL
TRIALS
INFORMATION
SUBSPECIALTY
CASE
REFERRAL
LITERATURE
SEARCHES
AND
OTHER
INFORMATION
THE
SERVICE
IS
DESIGNED
FOR
HEALTH
CARE
PROFESSIONALS
RATHER
THAN
PATIENTS
FAMILIES
OR
OTHERS
WHO
HAVE
ALTERNATE
SOURCES
OF
INFORMATION
OR
MATERIALS
WHEN
A
HEALTH
CARE
PROFESSIONAL
CALLS
THE
NEW
SERVICE
THE
CALL
IS
TAKEN
BY
EITHER
A
CLINICAL
PHARMACIST
PRIMARY
CARE
PHYSICIAN
OR
FAMILY
NURSE
PRACTITIONER
ALL
STAFF
MEMBERS
HAVE
EXTENSIVE
EXPERIENCE
IN
OUTPATIENT
AND
INPATIENT
PRIMARY
CARE
FOR
PEOPLE
WITH
HIVRELATED
DISEASES
THE
CONSULTANT
ASKS
FOR
PATIENTSPECIFIC
INFORMATION
INCLUDING
CELL
COUNT
CURRENT
MEDICATIONS
SEX
AGE
AND
THE
PATIENTS
HIV
HISTORY
THIS
NATIONAL
SERVICE
HAS
GROWN
OUT
OF
A
LOCAL
EFFORT
THAT
HICNET
MEDICAL
NEWSLETTER
PAGE
VOLUME
NUMBER
APRIL
RESPONDED
TO
NEARLY
CALLS
FROM
HEALTH
CARE
PROVIDERS
IN
NORTHERN
CALIFORNIA
THE
INITIAL
PROJECT
WAS
FUNDED
BY
HRSAS
BUREAU
OF
HEALTH
PROFESSIONS
THROUGH
ITS
COMMUNITY
PROVIDER
AIDS
TRAINING
CPAT
PROJECT
AND
BY
THE
AMERICAN
ACADEMY
OF
FAMILY
PHYSICIANS
WHEN
PROVIDERS
EXPAND
THEIR
KNOWLEDGE
THEY
ALSO
IMPROVE
THE
QUALITY
OF
CARE
THEY
ARE
ABLE
TO
PROVIDE
TO
THEIR
PATIENTS
SAID
HRSA
ADMINISTRATOR
ROBERT
G
HARMON
MD
MPH
THIS
PROJECT
WILL
BE
A
GREAT
RESOURCE
FOR
HEALTH
CARE
PROFESSIONALS
AND
THE
HIVAIDS
PATIENTS
THEY
SERVE
THIS
SERVICE
HAS
OPENED
A
NEW
MEANS
OF
COMMUNICATION
BETWEEN
HEALTH
CARE
PROFESSIONALS
AND
EXPERTS
ON
HIV
CARE
MANAGEMENT
SAID
HRSAS
ASSOCIATE
ADMINISTRATOR
FOR
AIDS
AND
DIRECTOR
OF
THE
BUREAU
OF
HEALTH
RESOURCES
DEVELOPMENT
G
STEPHEN
BOWEN
MD
MPH
PROVIDERS
WHO
TREAT
PEOPLE
WITH
HIV
OR
AIDS
HAVE
ACCESS
TO
THE
LATEST
INFORMATION
ON
NEW
DRUGS
TREATMENT
METHODS
AND
THERAPIES
FOR
PEOPLE
WITH
HIV
OR
AIDS
HRSA
IS
ONE
OF
EIGHT
US
PUBLIC
HEALTH
SERVICE
AGENCIES
WITHIN
HHS
AIDS
HOTLINE
NUMBERS
FOR
CONSUMERS
CDC
NATIONAL
AIDS
HOTLINE
FOR
INFORMATION
IN
SPANISH
AIDS
CLINICAL
TRIALS
ENGLISH
SPANISH
HICNET
MEDICAL
NEWSLETTER
PAGE
CUT
HERE
THIS
IS
THE
LAST
PART
INTERNET
DAVIDSTATCOM
FAX
BITNET
FIDONET
AMATEUR
PACKET
